Update shared on24 Aug 2025
Fair value Increased 4.79%The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12.
What's in the News
- Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.
- Activist investor ASL Strategic Value Fund urged shareholders to vote against company board nominees, demanded an independent election monitor for the annual meeting, and pushed for monetization of LUMRYZ, which recently received orphan drug designation for idiopathic hypersomnia.
- The U.S. Court of Appeals unanimously upheld FDA approval of LUMRYZ, supporting Avadel in a legal dispute initiated by Jazz Pharmaceuticals.
- Avadel was added to the S&P TMI Index.
- New clinical data highlighted LUMRYZ’s efficacy and tolerability in treating narcolepsy, including improvements in sleepiness, reduced hallucination events, long-term safety, and positive patient outcomes compared to other oxybate treatments.
Valuation Changes
Summary of Valuation Changes for Avadel Pharmaceuticals
- The Consensus Analyst Price Target has risen slightly from $18.25 to $19.12.
- The Consensus Revenue Growth forecasts for Avadel Pharmaceuticals has risen slightly from 25.3% per annum to 26.4% per annum.
- The Future P/E for Avadel Pharmaceuticals has risen slightly from 16.02x to 16.53x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.